Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

liraglitude

- PMLiVE

EMA backs drugs from Novo, Otsuka, AZ, Janssen, GSK

Nine new branded medicines recommended for use in Europe

- PMLiVE

Pharma firms ramp up Cancer Drugs Fund pressure

Novartis, Roche and Sanofi join forces to highlight public attitudes to medicines access

- PMLiVE

NICE demands more data for Sanofi’s oral MS drug

UK body won't recommend Aubagio for NHS use based on current information

Sanofi reception

Sanofi wins EU approval for second MS drug in a month

EC approves Lemtrada weeks after Aubagio gets greenlight

- PMLiVE

Novo Nordisk’s Victoza shows Alzheimer’s benefits

UK scientists say the diabetes drug could reverse effects of dementia

- PMLiVE

Sanofi pulls Lyxumia’s US filing

Says will resubmit diabetes drug for FDA approval in 2015

Bristol-Myers Squibb (BMS) building

BMS’ Yervoy fails prostate cancer trial

Unable to improve overall survival in phase III

Bristol-Myers Squibb (BMS) building

BMS says it defends Sprycel patent in India

Blocks attempts to issue compulsory license for leukaemia drug

- PMLiVE

Sanofi plans its mobile diabetes future

Next phase of iBGStar project will focus on wider connectivity

- PMLiVE

New head for Novo Nordisk in North America

US diabetes care specialist Novo Nordisk Inc has a new president

- PMLiVE

Eisai launches online obesity awareness drive

Wants US employers to realise the cost of obesity

- PMLiVE

MannKind celebrates as inhaled insulin clears pivotal trials

Closing in on approval of Afrezza

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links